Brandon Weckbaugh, MD, an oncology fellow at 海角论坛 is interview on OncLive
The treatment landscape of non–small cell lung cancer (NSCLC) continues to expand with potential biomarkers that are under investigation, as well as novel agents that could potentially target them. What was once a major area of unmet need has experienced an explosion of new research, said Brandon Weckbaugh, MD. .